Abstract

The insulin-like growth factor 1 (IGF1) signalling pathway has important roles in regulating cellular proliferation and apoptosis. Converging results from epidemiological research and in vivo carcinogenesis models indicate that high levels of circulating IGF1 are associated with increased risk of several common cancers. Ongoing research seeks to clarify the mechanisms underlying these observations and to determine the extent to which IGF physiology influences patterns of cancer incidence. Various therapeutic strategies that target the IGF1 receptor have demonstrated impressive antineoplastic activity in laboratory models, and clinical trials of several novel drug candidates are planned.

Author affiliations

1. Department of Oncology, McGill University and Lady Davis Research Institute, 3999 Rue Côte Sainte Catherine, Montréal, Québec H3T 1E2, Canada.
2. Channing Laboratory and Department of Epidemiology, Harvard University, Boston, Massachusetts, USA.

Correspondence to: Email: michael.pollak@mcgill.ca

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.